Alopecia Pipeline Review, H1 2019 - Therapeutic Assessment of 28 Companies & Drug Profiles - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Mar 25, 2019--The “Alopecia - Pipeline Review, H1 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.
Alopecia - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Alopecia (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Alopecia (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Alopecia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 5, 15, 5, 1, 16, 9 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.
Alopecia (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
- The pipeline guide provides a snapshot of the global therapeutic landscape of Alopecia (Dermatology).
- The pipeline guide reviews pipeline therapeutics for Alopecia (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Alopecia (Dermatology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Alopecia (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Alopecia (Dermatology)
Key Topics Covered:
- Alopecia - Overview
- Alopecia - Therapeutics Development
- Alopecia - Therapeutics Assessment
- Alopecia - Companies Involved in Therapeutics Development
- Alopecia - Drug Profiles
- Alopecia - Dormant Projects
- Alopecia - Discontinued Products
- Alopecia - Product Development Milestones
- Aclaris Therapeutics Inc
- Allergan Plc
- Almirall SA
- Berg LLC
- BiologicsMD Inc
- BirchBioMed Inc
- Brickell Biotech Inc
- Cassiopea SpA
- Concert Pharmaceuticals Inc
- Dong-A Socio Holdings Co Ltd
- Eli Lilly and Co
- Energenesis Biomedical Co Ltd
- Follica Inc
- Histogen Inc
- Japan Tobacco Inc
- JW Pharmaceutical Corp
- Kuhnil Pharmaceutical Co Ltd
- Lee’s Pharmaceutical Holdings Ltd
- Nepsone ehf
- OliX Pharmaceuticals Inc
- Pfizer Inc
- Phio Pharmaceuticals Corp
- Portola Pharmaceuticals Inc
- Quark Pharmaceuticals Inc
- Samumed LLC
- Suzhou Ribo Life Sciences Co Ltd
- Taisho Pharmaceutical Holdings Co Ltd
- Tigo GmbH
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/4mx3cp/alopecia_pipeline?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20190325005581/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Immune Disorders Drugs
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 03/25/2019 11:59 AM/DISC: 03/25/2019 11:59 AM